Companies · Biotechnology

Peytant Solutions, Inc.

Plymouth · Biotechnology

Diligence memoA one-page analyst read on Peytant Solutions, Inc. — recommendation, valuation, rhythm, risks.
$4.9M
Total raised · real
4
Rounds
0.3×
Latest step-up
Top 58%
Sector rank · raised
Seed
Latest stage · inferred · Mon Feb 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Peytant Solutions, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.14× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.4 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Peytant Solutions, Inc. is one of 4291 Biotechnology companies tracked from Plymouth. By capital raised it ranks mid-pack (ahead of 43% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2023-02-06
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2015-08-19 Raised $577K (real) Modeled valuation $32M (est)Pre-Seed2015Seed · 2017-07-27 Raised $1.2M (real) Modeled valuation $52M (est)Seed2017Pre-Seed · 2017-07-27 Raised $860K (real) Modeled valuation $47M (est)Pre-Seed2017Seed · 2021-03-09 Raised $275K (real) Modeled valuation $8.3M (est)Seed2021Seed · 2023-02-06 Raised $1.5M (real) Modeled valuation $16M (est)Seed2023Seed · 2023-02-06 Raised $2.9M (real) Modeled valuation $30M (est)Seed2023Pre-Seed · 2023-02-06 Raised $900K (real) Modeled valuation $9.9M (est)Pre-Seed2023+$1.2M+$860K+$275K+$1.5M+$2.9M+$900KCumulative $8.2M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$577K · 2015
Seed$1.2M · 2017
Bridge · Seed-stage$860K · 2017smaller follow-on
Seed extension$275K · 2021
Seed extension$1.5M · 2023
Seed extension$2.9M · 2023
Bridge · Seed-stage$900K · 2023smaller follow-on

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$30.4M
Base estimate est.
$2.1M
Conservative case
$117.9M
Upside case
$14.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $31.8M · 2015-08-192015Seed · modeled $51.5M · 2017-07-27Pre-Seed · modeled $47.5M · 2017-07-27Seed · modeled $8.3M · 2021-03-09Seed · modeled $16.2M · 2023-02-06Seed · modeled $30.4M · 2023-02-06Pre-Seed · modeled $9.9M · 2023-02-062023
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
3.4 yr
Elapsed time used
3.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
15 mo
Avg between rounds
$656K/yr
Capital velocity
10.9 yr
On record since
2015
First round
7
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.7× of median
This company$4.9M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.5× of median
This company$900K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$30.4M
Sector median$64.2M

Raised more than 43% of sector peers (real $). Modeled value above 36% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #36 of 207.

This companyCohort peer
$10.0M$100.0M$1.0M$10.0MCapital raised (log)Mesentech Inc. · Seed Raised $3.9M · modeled $65.6M (est)Marlinspike Therapeutics, Inc. · Seed Raised $3.5M · modeled $64.3M (est)Microbial Machines, Inc. · Seed Raised $3.9M · modeled $63.6M (est)Pearl Diagnostics, Inc. · Seed Raised $3.5M · modeled $62.8M (est)Crossfire Medical Inc · Seed Raised $3.0M · modeled $57.5M (est)Design Pharmaceuticals, Inc. · Seed Raised $3.0M · modeled $56.9M (est)Tekv Holdings LLC · Seed Raised $4.0M · modeled $55.4M (est)Mi-Helper, Inc. · Seed Raised $4.0M · modeled $50.9M (est)Thelium Therapeutics Inc. · Seed Raised $3.1M · modeled $50.7M (est)Turtle Health, Inc. · Seed Raised $2.7M · modeled $49.1M (est)Accufix Holdings, Inc. · Seed Raised $4.2M · modeled $46.7M (est)Kyttaro Ltd · Seed Raised $5.2M · modeled $45.5M (est)Peytant Solutions, Inc. (this company) Raised $4.9M · modeled $30.4M (est)Peytant Solutions, Inc.
CompanyStageRaised · realValue · estvs peer med.
Mesentech Inc.Seed$3.9M$65.6M4.61×
Marlinspike Therapeutics, Inc.Seed$3.5M$64.3M4.52×
Microbial Machines, Inc.Seed$3.9M$63.6M4.47×
Pearl Diagnostics, Inc.Seed$3.5M$62.8M4.41×
Crossfire Medical IncSeed$3.0M$57.5M4.04×
Design Pharmaceuticals, Inc.Seed$3.0M$56.9M4.00×
Tekv Holdings LLCSeed$4.0M$55.4M3.89×
Mi-Helper, Inc.Seed$4.0M$50.9M3.58×
Thelium Therapeutics Inc.Seed$3.1M$50.7M3.56×
Turtle Health, Inc.Seed$2.7M$49.1M3.45×
Accufix Holdings, Inc.Seed$4.2M$46.7M3.28×
Kyttaro LtdSeed$5.2M$45.5M3.20×
Peytant Solutions, Inc. this companySeed$4.9M$30.4M2.14×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$577K2015-08-19$3.2M$31.8M85%
Seed$1.2M2017-07-27$5.8M$51.5M90%
Pre-Seed$860K2017-07-27$4.8M$47.5M90%
Seed$275K2021-03-09$1.4M$8.3M90%
Seed$1.5M2023-02-06$7.7M$16.2M90%
Seed$2.9M2023-02-06$14.5M$30.4M90%
Pre-Seed$900K2023-02-06$5.0M$9.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$577K2015-08-19
    • First recorded raise — entered as Pre-Seed.
    • 8 investors on this round.
  2. Seed$1.2M2017-07-27
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 11 investors on this round.
  3. Pre-Seed$860K2017-07-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  4. Seed$275K2021-03-09
    • Raised again after 43 mo — slower than the ~14 mo sector norm.
    • Round 3.1× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  5. Seed$1.5M2023-02-06
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 5.6× larger than the prior — scaling up.
    • 8 investors on this round.
  6. Seed$2.9M2023-02-06
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.9× larger than the prior — scaling up.
    • 19 investors on this round.
  7. Pre-Seed$900K2023-02-06
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.2× smaller than the prior — bridge or down round.
    • 3 investors on this round.
Intelligence
2024 ~Q2
Modeled next raise · ~15mo cadence
$900K
Modeled next size est.range $900K$1.4M
0.3×
Last step-up
$656K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Craig Walker4 other2023-02
Steven J. Healy4 other2021-03
Steven Healy2 other2017-07
Craig J. Walker1 other2021-03
James Ness1 other2015-08
Jeffrey Chambers1 other2015-08
Bruce Faulken2017-07
Bruce J. Faulken2021-03
Clay Anselmo2017-07
Clay J. Anselmo2021-03
Jeffrey J. Chambers2021-03
John Schorgl2015-08
Registry & provenance

Peytant Solutions, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1652372
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
BioHSV Holdings, Inc.BiotechnologySeed$5.0M$33.5Msame sector · same stage
Protein Forest, Inc.BiotechnologySeed$5.0M$33.3Msame sector · same stage
AvidBiotics Corp.BiotechnologySeed$4.8M$37.9Msame sector · same stage
Maxcyte, Inc.BiotechnologySeed$5.1M$33.8Msame sector · same stage
AnPac Bio-Medical Science Co., Ltd.BiotechnologySeed$4.7M$23.1Msame sector · same stage
Ibex Biosciences, LLCBiotechnologySeed$5.2M$25.4Msame sector · same stage
Neurodyn Life Sciences Inc.BiotechnologySeed$5.2M$28.9Msame sector · same stage
Nexgel, Inc.BiotechnologySeed$4.6M$37.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Pyxant Labs IncBiotechnologySeed$49.0M84%
PellePharm, Inc.BiotechnologySeries A$271.1M84%
BiomeSense, Inc.BiotechnologySeries A$22.4M83%
P2 Science, Inc.BiotechnologySeries B$619.5M83%
Pulmotect, Inc.BiotechnologySeries A$49.8M83%
Pneumeric, Inc.BiotechnologySeed$23.4M83%
Seedling Biosystems Inc.BiotechnologyPre-Seed$886K82%
Cytek BioSciences, Inc.BiotechnologySeries D+$4.5B82%
Frequently asked
How much funding has Peytant Solutions, Inc. raised?
Peytant Solutions, Inc. has raised approximately $4.9M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Peytant Solutions, Inc.'s estimated valuation?
Provath's modeled valuation for Peytant Solutions, Inc. is approximately $30.4M (modeled range $2.1M–$117.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Peytant Solutions, Inc. at?
Peytant Solutions, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Feb 06.
What does Peytant Solutions, Inc. do and where is it based?
Peytant Solutions, Inc. operates in the Biotechnology sector, based in Plymouth.
Explore related

See where Peytant Solutions, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Peytant Solutions, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.